COH-SR4

COH-SR4 is a novel small molecule 1,3-bis(3,5-dichlorophenyl) urea compound developed by researchers at the City of Hope National Medical Center. It is primarily investigated for the treatment of malignant melanoma. The drug acts as a multi-target inhibitor, specifically targeting glutathione S-transferase (GST) activity and activating the AMP-activated protein kinase (AMPK) pathway. Preclinical studies demonstrate that COH-SR4 induces G2/M phase cell cycle arrest and apoptosis in melanoma cells. It also inhibits key oncogenic signaling nodes, including the Akt pathway, and reduces markers of angiogenesis (CD31) and proliferation (Ki67). In vivo studies in mouse models have shown significant reduction in tumor burden with oral administration, suggesting potential for development as a single agent or in combination therapies for aggressive and clinically resistant melanomas.

Other names

1,3-bis(3,5-dichlorophenyl) urea